Role of Kasai procedure in surgery of hilar bile duct strictures

AIM:To assess the application of the Kasai procedure in the surgical management of hilar bile duct strictures.METHODS:Ten consecutive patients between 2005 and 2011 with hilar bile duct strictures who underwent the Kasai procedure were retrospectively analyzed.Kasai portoenterostomy with the placement of biliary stents was performed in all patients.Clinical characteristics,postoperative complications,and long-term outcomes were analyzed.All patients were followed up for 2-60 mo postoperatively.RESULTS:Patients were classified according to the Bismuth classification of biliary strictures.There were two Bismuth Ⅲ and eight Bismuth Ⅳ lesions.Six lesions were benign and four were malignant.Of the benign lesions,three were due to post-cholecystectomy injury,one to trauma,one to inflammation,and one to inflammatory pseudotumor.Of the malignant lesions,four were due to hilar cholangiocarcinoma.All patients underwent Kasai portoenterostomy with the placement of biliary stents.There were no perioperative deaths.One patient experienced anastomotic leak and was managed conservatively.No other complications occurred perioperatively.During the follow-up period,all patients reported a good quality of life.CONCLUSION:The Kasai procedure combined with biliary stents may be appropriate for patients with hilar biliary stricture that cannot be managed by standard surgical methods.

Impact of lymph node micrometastasis in hilar bile duct carcinoma patients

AIM- To immunohistochemicaUy examine micrometastasis and VEGF-C expression in hilar bile duct carcinoma （HBDC） and to evaluate the clinical significance of the results. METHODS： A total of 361 regional lymph nodes from 25 patients with node-negative HBDC were immunostained with an antibody against cytokeratins 8 and 18 （CAM 5.2）, and immunohistochemical staining of VEGF-C was performed in 34 primary resected tumors. RESULTS： Lymph node micrometastasis was detected in 6 （24%） of the 25 patients and 10 （2.8%） of the 361 lymph nodes. Patients with micrometastasis showed significantly poorer survival rates than those without （P= 0.025）. VEGF-C expression was positive in 17 （50%） of 34 HBDC, and significantly correlated with lymph node metastasis （P=0.042） and microscopic venous invasion （P=0.035）. CONCLUSIONS： It is suggested that immunohistochemically detected lymph node micrometastasis has an impact on the outcome of HBDC. VEGF-C expression is highly correlated with lymph node metastasis in HBDC and might therefore be a useful predictor.

SURGICAL TREATMENT OF HILAR BILE DUCT CARCINOMA

From June, 1986 to June 1989, 24 cases of hilar bile duct carcinoma were explored in the Surgical Department of General Hospital of PLA, 16/24 cases were resected, a resectability rate of 66%. The increase of resectability rate was due to earlier recognition of this condition and the extension of surgery, including major resection of liver as well as radical dissection of the hepato-duodenal ligament and repairative operations on the blood vessels. Among these 16 cases, major hepatic resection was performed in 10 cases, in which, 3 cases of resections of the middle lobe of the liver were done instead of right or extended right lobectomy. No operative mortality in the 30 days' postoperative period, but the postoperative morbidity rate was still high and most of the complications were related to biliary leakage and infection. Three patients died in the follow up period at 6, 14 and 15 months respectively. All of them died from biliary infection. The remaining 13 patients were still alive, the longest being 40 months and the average living time was 16.1 months. Probably, lowering of the operative mortality rate and morbidity rate are still the most important considerations in the surgical treatment of hilar carcinoma at the present time. Extensive liver resection especially on the right side, carried a high mortality rate in the deeply jaundiced patients. We considered that preoperative PTCD was of much less value than that used in lower bile duct obstruction such as tumors of the periampullary region. Preservation of the superior and posterior portion of the right lobe of the liver may be of advantages as to lowering postoperative hepatic failure and infection of the right subphrenic space as observed in this series of cases.

New tapered metallic stent for unresectable malignant hilar bile duct obstruction

AIM: To examine the usefulness of a new tapered metallic stent(MS) in patients with unresectable malignant hilar bile duct obstruction.METHODS: This new tapered MS was placed in 11 patients with Bismuth Ⅱ or severer unresectable malignant hilar bile duct obstruction, as a prospective study. The subjects were six patients with bile duct carcinoma, three with gallbladder cancer, and two with metastatic bile duct obstruction. Stenosis morphology was Bismuth Ⅱ: 7, Ⅲa: 3, and Ⅳ: 1. UMIN Clinical Trial Registry(UMIN000004758).RESULTS: MS placement was 100%(11/11) successful. There were no procedural accidents. The mean patency period was 208.401 d, the median survival period was 142.000 d, and the mean survival period was 193.273 d. Occlusion rate was 36.4%(4/11); the causes of occlusion were ingrowth and overgrowth in 2 patients each, 18.2%, respectively. Patients with occlusion underwent endoscopic treatment one more time and all were treatable. CONCLUSION: The tapered MS proved useful in patients with unresectable malignant hilar bile duct obstruction because it provided a long patency period, enabled re-treatment by re-intervention, and no procedural accidents occurred.

Application of multiple Roux-en-Y hepaticojejunostomy reconstruction by formation of bile hilar duct lake in the operation of hilar cholangiocarcinoma

BACKGROUND Hilar cholangiocarcinoma is the most common malignant tumor of the extrahepatic bile duct.Until now,radical resection has been the most effective method for the long-term survival of patients with the disease.However,many problems have emerged in the field of hepatobiliary surgery for a long time,including complex surgical procedures,low resection rate,and postoperative complications.We have adopted the“multiple Roux-en-Y hepaticojejunostomy reconstruction by formation of a bile duct lake”technique in the treatment of hilar cholangiocarcinoma since 2008,and obtained satisfactory short-and longterm results.AIM To examine the feasibility of the application of multiple Roux-en-Y hepaticojejunostomy reconstruction by formation of a bile duct lake in the operation of hilar cholangiocarcinoma METHODS A retrospective analysis was performed for the clinical data,surgical methods,and results of 76 patients with hilar cholangiocarcinoma who were treated with hilar bile duct lake-forming multiple Roux-en-Y hepaticojejunostomy reconstruction at Gansu Provincial Hospital.RESULTS In all 76 cases,the operation was successful and no operative death occurred.The mean(range)operation time was 215.4±53.5 min(124–678 min),and the amount of bleeding during the operation was 428.2±63.8 mL(240–2200 mL).The overall 1-year survival rate was 78.9%,and the 3-year survival rate was 32.8%.CONCLUSION The multiple Roux-en-Y hepaticojejunostomy reconstruction technique with formation of a bile duct lake is safe and effective for the surgical treatment of hilar cholangiocarcinoma.

Metachronous bile duct cancer nine years after resection of gallbladder cancer

We report a rare case of a 74-year-old man with metachronous gallbladder cancer and bile duct cancer who underwent curative resection twice, with the operations nine years apart. At the age of 65 years, the patient underwent a cholecystectomy and resection of the liver bed for gallbladder cancer. This was a welldifferentiated adenocarcinoma, with negative resection margins （T2NOM0, stage Ⅰ B）. Nine years later, during a follow-up examination, abdominal computed tomography and MRCP showed an enhanced 1.7 cm mass in the hilum that extended to the second branch of the right intrahepatic bile duct. We diagnosed this lesion as a perihilar bile duct cancer, Bismuth type Ⅲ a, and performed bile duct excision, right hepatic Iobectomy and Roux-en-Y hepaticojejunostomy. The histological diagnosis was a well-differentiated adenocarcinoma with one regional lymph node metastasis （TINIM0, stage Ⅱ B）. Twelve months after the second operation, the patient is well, with no signs of recurrence. This case is compared with 11 other cases of metachronous biliary tract cancer published in the world medical literature.

Pathological aspects of so called "hilar cholangiocarcinoma"

Cholangiocarcinoma(CC) arising from the large intrahepatic bile ducts and extrahepatic hilar bile ducts share clinicopathological features and have been called hilar and perihilar CC as a group.However,"hilar and perihilar CC" are also used to refer exclusively to the intrahepatic hilar type CC or,more commonly,the extrahepatic hilar CC.Grossly,a major distinction can be made between papillary and non-papillary tumors.Histologically,most hilar CCs are well to moderately differentiated conventional type(biliary) carcinomas.Immunohistochemically,CK7,CK20,CEA and MUC1 are normally expressed,being MUC2 positive in less than 50% of cases.Two main premalignant lesions are known:biliary intraepithelial neoplasia(BilIN) and intraductal papillary neoplasm of the biliary tract(IPNB).IPNB includes the lesions previously named biliary papillomatosis and papillary carcinoma.A series of 29 resected hilar CC from our archives is reviewed.Most(82.8%) were conventional type adenocarcinomas,mostly well to moderately differentiated,although with a broad morphological spectrum;three cases exhibited a poorly differentiated cell component resembling signet ring cells.IPNB was observed in 5(17.2%),four of them with an associated invasive carcinoma.A clear cell type carcinoma,an adenosquamous carcinoma and two gastric foveolar type carcinomas were observed.

Risk factors and classifications of hilar cholangiocarcinoma

Cholangiocarcinoma is the second most common primary malignant tumor of the liver.Perihilar cholangiocarcinoma or Klatskin tumor represents more than 50% of all biliary tract cholangiocarcinomas.A wide range of risk factors have been identified among patients with Perihilar cholangiocarcinoma including advanced age,male gender,primary sclerosing cholangitis,choledochal cysts,cholelithiasis,cholecystitis,parasitic infection(Opisthorchis viverrini and Clonorchis sinensis),inflammatory bowel disease,alcoholic cirrhosis,nonalcoholic cirrhosis,chronic pancreatitis and metabolic syndrome.Various classifications have been used to describe the pathologic and radiologic appearance of cholangiocarcinoma.The three systems most commonly used to evaluate Perihilar cholangiocarcinoma are the Bismuth-Corlette(BC) system,the Memorial Sloan-Kettering Cancer Center and the TNM classification.The BC classification provides preoperative assessment of local spread.The Memorial Sloan-Kettering cancer center proposes a staging system according to three factors related to local tumor extent:the location and extent of bile duct involvement,the presence or absence of portal venous invasion,and the presence or absence of hepatic lobar atrophy.The TNM classification,besides the usual descriptors,tumor,node and metastases,provides additional information concerning the possibility for the residual tumor(R) and the histological grade(G).Recently,in 2011,a new consensus classification for the Perihilar cholangiocarcinoma had been published.The consensus was organised by the European Hepato-PancreatoBiliary Association which identified the need for a new staging system for this type of tumors.The classification includes information concerning biliary or vascular(portal or arterial) involvement,lymph node status or metastases,but also other essential aspects related to the surgical risk,such as remnant hepatic volume or the possibility of underlying disease.

Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma

BACKGROUND: Hepatic hilar cholangiocarcinoma can be diagnosed early with the progress in diagnostic imaging, and thus the rate of resection of the tumor has increased markedly. To assess the effectiveness of resection, we reviewed 185 cases of hepatic hilar cholangiocarcinoma diagnosed and treated at our hospital. METHODS: The clinical data of 185 patients with hepatic hilar cholangiocarcinoma who had been treated surgically from 1972 to 2006 were retrospectively analyzed. RESULTS: The records of the 185 patients were divided into first stage (1972-1986) or second stage (1987-2006) according to the incidence of the tumor and its resection rate. Primary symptoms included upper abdominal discomfort or pain, anorexia, tiredness, weight loss and progressive jaundice. Ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and magnetic resonance cholangiopancreatography (MRCP) were first line methods for atraumatic diagnosis. If the patients displayed intrahepatic bile duct dilatation or were diagnosed as suffering from extrahepatic obstructive jaundice, percutaneous transhepatic cholangiography (PTC), MRCP or endoscopic retrograde cholangiopancreatography (ERCP) should be used. In this series, 87 patients underwent resection of the tumor (47.0%). Of the 87 patients, 43 received radical resection and 44 palliative resection. Fifteen patients underwent resection in the first stage and 72 in the second stage. A total of 74 patients were followed up after the resection. The median survival time of the radical resection group was 37 months and that of the palliative resection group was 17 months (P<0.001). The other 62 patients receiving no resection died within 1.5 years. CONCLUSIONS: Once patients are diagnosed with hepatic hilar cholangiocarcinoma, they should undergo exploratory laparotomy. Resection is the most effective method for the treatment of hepatic hilar cholangiocarcinoma.

ERCP与经口胰胆管镜技术置入胆管支架在高位胆管癌中的疗效对比分析

目的探讨经ERCP与经口胰胆管镜技术行胆管支架置入在高位胆管癌中的疗效。方法回顾性分析2021年1月至2023年9月在南阳市中心医院行胆管支架置入的136例高位胆管癌患者临床资料。根据胆管支架置入方式分为ERCP组(86例)和经口胰胆管镜组(50例)。比较两组患者年龄、相关检验指标、住院天数、术后并发症、肝衰竭发生率、黄疸缓解率、支架材质及通畅率等情况。结果所有患者均成功完成手术。两组在术后肝衰竭发生率、黄疸缓解率、不同材质支架在术后并发症及短期通畅率方面对比,无明显统计学意义(P>0.05)。两组患者术后总的并发症比较,差异有统计学意义(t=12.02,P<0.05),其中术后胆道感染、术后出血相比较,ERCP组分别为26.7%、11.6%,明显高于经口胰胆管镜组的10.0%、2.0%(2=5.42,3.94;P<0.05);两组患者平均住院天数比较,经口胰胆管镜组(10.78±2.17)d<ERCP组(12.91±2.96)d,差异有统计学意义(P<0.05);两组患者手术前后肝功能明显改善,相关检验指标下降明显(P<0.05);塑料支架与金属支架在术后并发症及短期通畅率方面对比,无明显差异(P>0.05),在通畅时间>6个月的情况下,金属支架通畅率明显高于塑料支架(P<0.05)。结论经ERCP与经口胰胆管镜技术置入胆管支架对于缓解高位胆管癌临床症状有效,均可提高患者生存质量。其中经口胰胆管镜技术并发症发生率低、恢复快、优势更大,但花费较高;塑料支架对预期生存时间较短的患者有益,金属支架更适用于预期生存时间较长的患者。

经皮经肝门静脉栓塞术在肝门部胆管癌手术中的应用

目的探讨对肝门部胆管癌行扩大右半肝切除术前使用经皮经肝门静脉栓塞术(portalveinembolization,PVE)的疗效。方法2005年10月对1例伴有肝硬化的肝门部胆管癌施行经皮经肝门静脉栓塞术(percutaneousportalveinembolization,PTPE),记录肝脏在血流动力学、体积、功能、病理方面的改变。结果PTPE术后第5天体温升至39.2℃,然后逐渐下降,同时伴有轻度右上腹痛,无恶心呕吐,未见腹腔出血及胆漏。PTPE术后左叶体积从417.0ml增加到522.4ml(肥大率125.2%);右叶体积从1041·3ml减少到1017·4ml(萎缩率97.7%);左叶占全肝的体积比从28.6%升至33·9%。左矢状部血流速度术前为12·8ml/s,术后当日、第6天分别为23·2、17·1ml/s。较原流量增加100%和39%(术后当日,第6天)。PTPE术后17d左肝胆汁的引流量超过右肝。PTPE术后34d患者接受扩大右半肝切除术,术中见肝左叶可见明显的肥大,肝脏5、6、7段(S5,6,7)与其余肝段间有明显的界限,术后3个月病情平稳。术后病理:栓塞叶门静脉狭窄及闭塞而肝细胞变性,坏死及凋亡。结论PVE能有效诱导未栓塞肝叶的肥大,从而提高对伴有肝损害的患者行扩大肝脏切除的安全性。

钙及维生素D_3治疗骨质疏松症349例疗效评价

目的 探讨钙剂及维生素D3 (VitD3 )治疗骨质疏松的临床效果。 方法 3 4 9例骨质疏松患者用不同方法的钙剂 (钙剂 ;钙 +VitD3 )治疗 18月。 结果 钙剂组 (乳酸钙 10 0 0mg ,每天 3次 ) 40 %患者症状改善 ,但骨量仍继续下降 ,而钙 +VitD3 治疗组 (钙尔奇D +阿尔法D3 ) 78%患者症状缓解 ,且骨量明显上升。 结论 虽然补钙不失为骨质疏松防治的基本方法 ,但补钙应慎重 ,钙剂的补充必须是有目的、有计划、有监测的 ,单纯高剂量补钙可能导致骨质疏松、髋部骨折发病率增高 ,需引起广泛重视 ,钙剂使用时要强调VitD3 的联合应用 ,活性VitD3 不仅是钙在人体被骨骼吸收、利用的载体 ,而且可以减轻钙剂对人体所致的副作用 。

肝门部胆管癌的治疗

目的评价外科治疗肝门部胆管癌(hilarbileductcancer,HBDC)的疗效。方法回顾性分析该科自1989年11月~1999年8月共收治HBDC31例。其中,行单纯胆肠内引流术共18例(组1),行支撑内引流加内外放疗共9例(组2),行网络化切除加支撑内引流与网络化切除加支撑内引流加内外放疗共4例(组3)。结果随访的结果表明:术后生存期为1周~10.5个月(组1),在组2中,除外2例无法完成放疗,其他7例术后生存期平均为21.2个月,在组3中,由于病例太少无法做相对可靠的分析,但疗效显著。(其中1例患者术后存活达8年零7个月)。3组病例中,严重的并发症包括胃肠道出血2例,肝肾综合征1例,肺炎1例(76岁),发热6例。结论肝门部胆管癌(HBDC)由于其部位特殊和早期诊断困难,手术切除率低而预后较差。在无法行手术切除的病例中,单纯胆肠内引流术能有效地缓解病情,对于合适的病例,内引流联合内外放疗是安全的,有效缓解病情且能取得显著疗效。

经皮肝胆管引流术在肝门部恶性肿瘤胆道梗阻中的应用

目的分析经皮肝胆管引流术(PTCD)在肝门部恶性肿瘤胆道梗阻中的治疗效果,探讨PTCD介入治疗的价值。方法将55例肝门部恶性肿瘤胆道梗阻患者按照手术适应评估结果分为PTCD组(30例经皮肝胆管引流术)和对照组(25例经内镜内支架植入术),观察PTCD组患者术前及术后生化指标,包括血清总胆红素(TB)、血清直接胆红素(DB)、血清丙氨酸转氨酶(ALT)、血清谷氨酸氨基转移酶(AST)和血清碱性磷酸酶(AKP),并且对2组患者进行术后随访,比较2组患者治疗有效率和术后生存时间。结果 PTCD组患者手术后1周与术前TB、DB、ALT、AST和APK比较变化明显,PTCD治疗后患者生化指标明显改善,差异具有统计学意义(P<0.05);PTCD组和内镜内支架植入组治疗有效率分别为83.3%和64.0%,生存时间分别为(7.5±2.6)个月和(4.8±2.8)个月,PTCD组明显优于内镜内支架植入,差异具有统计学意义(P<0.05)。结论患者PTCD治疗后,生化指标得到明显改善,术后生存时间显著延长,PTCD治疗可以作为临床上治疗肝门部恶性肿瘤胆道梗阻的有效手术方法。

肝门部胆管癌的外科治疗

目的 分析一个单位 1986-2 0 0 2年间治疗肝门部胆管癌的经验。方法 回顾 1986-2 0 0 2年在解放军总医院肝胆外科治疗 2 91例肝门部胆管癌的纪录 ,全部治疗均在单一的科室技术领导下进行 ,有一定的连贯性。外科治疗手段主要是依据手术中所发现的病理情况决定。根治性切除术的标准是指切除的边缘病理上未发现残留癌细胞者。结果 在我国 ,肝外胆管癌是并非少见的疾病 ,近年来手术治疗的病例数有增多倾向。然而 ,根治性切除手术有困难 ,甚至联合肝切除亦难以达到根治目的 ,因而根治性切除率只分别为 3 7.6%和 41.2 %。无切除术后 3 0d内死亡。有 4例病人于切除术后长期无瘤生存 ,5年以上生存率为 13 .3 % ;另有 2例病人亦生存达 5年以上 ,但癌复发 ,现仍在接受进一步治疗。结论 肝门部胆管癌是多态性的疾病 ,只是极少数表现为较“良性”的倾向 ,而绝大多数则于手术切除后易于复发 ,虽然手术似乎是已达治愈性。切除性治疗 ,甚至是姑息性切除 ,仍可以达到延长生命和提高生活质量的效果。

带蒂胆囊瓣修复肝门胆管狭窄(附53例报告)

目的提高良性肝门胆管狭窄的治疗效果.方法采用带血管蒂胆囊瓣肝门胆管成形术(plastics of hilar bile duct stricture,PHBDS)治疗合并肝内胆管结石的肝门胆管炎性狭窄,并回顾性分析我院近10年间行PHBDS及胆管空肠 Roux-en-Y吻合术(RYCJ)治疗的肝门胆管狭窄患者的临床资料.结果随访16～87个月,平均47个月.PHBDS组与RYCJ组术后胆管炎发生率分别为5.66%和21.88%,差异有统计学意义(P=0.010);胆管结石复发率分别为3.77% 和16.67%,差异有统计学意义 (P=0.021).结论 PHBDS术后远期效果优于RYCJ组.

MRI结合MRCP对肝门部胆管狭窄病因的评价

目的:探讨MRI结合MRCP对肝门部胆管狭窄病因的诊断价值。材料和方法:回顾性分析66例肝门部胆管狭窄患者的临床、MRI资料,所有病例均进行MR平扫、增强及MRCP检查,其中12例经ERCP证实、6例经PTC证实,48例经手术病理证实。结果:66例肝门部胆管狭窄患者中,26例损伤性狭窄,9例肝门部胆管癌,6例肝门部转移性肿瘤,14例炎性狭窄,4例胆管结石,Mirizzi综合征及硬化性胆管炎各2例,3例先天性胆管囊肿。胆管受累范围按Bismuth分级,MRI和MRCP均显示了胆管狭窄情况及病变特征。结论:MRI和MRCP对肝门部胆管狭窄病因的诊断具有重要价值,对指导临床采取正确的治疗措施具有重要意义。

移行吻合术治疗肝门部良性胆管狭窄的实验研究

目的探索"移行吻合术"治疗肝门部胆管良性狭窄的新术式,探讨肝门部胆管良性狭窄进行"移行吻合术"的理论基础与实际应用可行性.方法小型猪30头随机分为:A、B、C 3组.A组(对照组)于十二指肠上缘分离出一段长约2 cm的胆总管;B组分离胆总管同A组,然后以钳夹、电热等方法制造胆管组织物理损伤;C组制造胆管损伤同B组,术后监测小型猪的饮食二便,ALT,AST和胆红素等指标,待狭窄形成后再次开腹行移行吻合术.术后观察饮食、精神状态及尿液颜色,术前和术后1 d及术后每7 d测ALT、AST、T-BIL、D-BIL,全部手术完成3个月后处死,取部分肝组织,并用液氮保存,待做病理检查.结果从术前到术后30 d,A组ALT、AST、T-BIL、D-BIL等指标无明显变化,B组、C组相关指标均有明显变化(P<0.05).B组术后21d的ALT、AST、T-BIL、D-BIL较术前及术后14 d明显升高(P<0.05).C组行移行吻合术后,各项指标在移行吻合术后14、21 d较移行吻合前明显减低(P<0.05).结论 "移行吻合术"治疗小型猪肝门部胆管良性狭窄是切实可行的,为临床以"移行吻合术"治疗肝门部胆管狭窄提供了实验基础.

肝门部胆管癌223例临床分析

目的:探讨肝门部胆管癌临床分型、手术方式、组织病理等因素对预后的影响。方法:对223例肝门部胆管癌临床特征、手术方式、病理分化程度等资料进行回顾性分析。结果:1)223例中根治性切除85例,切除率38.1%,术后1、3、5年生存率分别为58.8%、30.9%、8.8%。姑息性治疗110例,中位生存期为8个月。未经外科治疗者28例,平均生存时间为5个月。2)行病理学检查132例,腺癌121例,占91.7%。高、中、低分化分别29例(24.0%)、43例(35.5%)、49例(40.5%)。根治性切除高中分化组,1、3、5年生存率分别为55.0%、40.0%、15.0%,低分化组为45.8%、16.7%、0。3)按照Bismuth分型法Ⅰ型占20.1%,Ⅱ型占23.2%,Ⅲa型占10.3%,Ⅲb型占23.2%,Ⅳ型占7.2%,未分型者占16.0%。结论:1)根治性切除是提高肝门部胆管癌远期疗效的关键。2)肝门部胆管癌的低分化癌占有相当大比例,且病理分化程度与预后关系密切。3)肝门部胆管癌Bismuth分型法尚有一定局限性,仍需改进。

肝门部胆管声像在鉴别婴儿肝炎综合征与胆道闭锁中的应用价值

目的探讨肝门部胆管声像在鉴别胆道闭锁(BA)与婴儿肝炎综合征(IHS)中的应用价值。方法回顾分析BA与IHS患儿的超声声像资料,比较两组肝门部胆管声像:管腔显示率、三角带征(TC征)阳性率两项指标。结果两组患儿肝门部胆管管腔显示率、TC征阳性率及联合肝门部胆管管腔显示率+TC征阳性率相比较,差异均有统计学意义(P<0.05);BA组肝门部胆管管腔显示率(23.5%)显著低于IHS组(90.9%);BA组TC征阳性率(41.2%)显著高于IHS组(0);BA组肝门部胆管管腔显示不清+TC征阳性率为41.2%,而IHS组为0;IHS组肝门部胆管管腔显示清晰+TC征阴率为90.9%,而BA组为29.4%。结论肝门部胆管管腔显示情况对鉴别BA与IHS具有重要价值,而肝门部胆管管腔联合TC征显示情况可进一步鉴别两者。